Experience with erlotinib in the treatment of non-small cell lung cancer
L Landi, F Cappuzzo - Therapeutic Advances in Respiratory …, 2015 - journals.sagepub.com
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …
Erlotinib in the first-line treatment of non-small-cell lung cancer
M D'Arcangelo, F Cappuzzo - Expert review of anticancer therapy, 2013 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
B Piperdi, R Perez-Soler - Drugs, 2012 - Springer
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments
C Gridelli, P Maione, MA Bareschino… - Anticancer …, 2010 - ar.iiarjournals.org
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Y Wang, G Schmid-Bindert… - Therapeutic advances in …, 2012 - journals.sagepub.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients
M Santarpia, TM De Pas, G Altavilla, L Spaggiari… - Future …, 2013 - Future Medicine
Erlotinib is an orally administered small-molecule inhibitor of EGF receptor (EGFR) tyrosine
kinase that is approved for the treatment of non-small-cell lung cancer (NSCLC) and …
kinase that is approved for the treatment of non-small-cell lung cancer (NSCLC) and …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
GR Oxnard, VA Miller - Oncology, 2010 - search.proquest.com
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
[HTML][HTML] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
T Fong, D Morgensztern, R Govindan - Journal of Thoracic Oncology, 2008 - Elsevier
Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib
and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer …
and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer …